Figure 2
Figure 2. TTNT for low-dose methotrexate across treatment lines. Patients receiving low-dose methotrexate as first-line, mid-line (2nd-4th line), or late-line (5th line and later) therapy had significantly different TTNT (P = .0008). The longest TTNT was with mid-line use.

TTNT for low-dose methotrexate across treatment lines. Patients receiving low-dose methotrexate as first-line, mid-line (2nd-4th line), or late-line (5th line and later) therapy had significantly different TTNT (P = .0008). The longest TTNT was with mid-line use.

Close Modal

or Create an Account

Close Modal
Close Modal